BBIO ▲ +2.0% - BridgeBio Pharma, Inc.
$BBIO - BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
06-OCT-2026 04:01 PM ET
Share this post
More filings for $BBIO
BBIO ▲ +2.0% - BridgeBio Pharma, Inc.Oct 6, 2026BBIO ▲ +0.9% - BridgeBio Pharma, Inc.Oct 6, 2026BBIO ▲ +1.3% - BridgeBio Pharma, Inc.Oct 6, 2026BBIO ▼ -1.5% - BridgeBio Pharma, Inc.Oct 5, 2026BBIO ▲ +1.2% - BridgeBio Pharma, Inc.Oct 5, 2026BBIO ▲ +0.4% - BridgeBio Pharma, Inc.Sep 23, 2026
View full $BBIO filing history →💬 Comments
Loading comments…
Leave a comment